Grail, a genetic testing company, has partnered with PINC AI, the technology and services platform of healthcare improvement group Premier Inc., to identify patients that may benefit from using Grail’s multi-cancer early detection blood test Galleri.
PINC AI plans to leverage its AI-powered clinical decision support platform to identify patients with higher risks of cancer who would benefit from early testing and alert clinics to these patients. The alert system will be first tested with the Indianapolis-based Community Health Network health system.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.